CANO-ACIO CLINICAL LECTURESHIP The development and implementation of a subcutaneous immunoglobulin (SCIG) program at CancerCare Manitoba

Erin Streu

Abstract


The CANO-ACIO Clinical Lectureship highlights an innovative nursing program that improves patient care and quality of life for individuals on the cancer journey. The opportunity to share the details of the subcutaneous immunoglobulin program from CancerCare Manitoba (CCMB) with oncology nurses from across Canada is a privilege. Not only because our program offers patients diagnosed with cancer the opportunity to receive their supportive immunoglobulin treatment at home, but because it represents an opportunity for nurses to engage and empower patients in their care. This program demonstrates how an opportunity to be innovative and implement a change that is patient-centred, nurse-initiated, and meaningful has led to significant positive outcomes for our patients and institution. 


Full Text:

PDF

References


CCMB Practice Guideline. (2015). Disease Management Consensus Recommendations for the Management of Chronic Lymphocytic Leukemia. Available at www.cancercare.mb.ca.

CLL Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. (1988). Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. NEJM, 319(14), 902.

Compagno, N., Malipiero, G., Cinetto, F., & Agostini, C. (2014). Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Frontiers in Immunology, 5(626), 1–6.

Ducruet, T., Levasseur, M.C., Des Roche, A., Kafal, A., Dicaire, R., & Haddad, E. (2013). Pharmacoeconomic advantages of subcutaneous versus intravenous treatment in a Canadian pediatric center. Journal of Allergy and Clinical Immunology, 131, 585–590.

Freeman, J.A., Crassini, K.R., Best, O.G., Forsyth, C.J., Mackinlay, Han, et al. (2013). Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic leukemia. Leukemia Lymphoma, 54(1), 99–104.

Gardulf, A., Hammarstrom, L., & Smith, C.I. (1991). Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet, 338, 162–166.

Gardulf, A., Nicolay, U., Math, D., Asensio, O., Bernatowska, E., Bock, A., et al. (2004). Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. Journal of Allergy and Clinical Immunology, 114, 936–942.

Gerth, W.C., Betschel, S.D., & Zbrozek, A.S. (2014). Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada. Allergy, Asthma and Clinical Immunology, 10(23).

Greer, J.P., Arber, D.A., Glader, B., List, A., Means, R.T., Paraskevas, F., & Rodgers, G. (Eds.). (2014). Wintrobe’s clinical hematology (13th ed.). Philadelphia, PA: Lippincott Williams and Wilkins.

Jolles, S., & Sleasman, J.W. (2011). Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: A practical approach. Advances in Therapy, 28(7), 521–533.

Martin, A., Lavie, L., Goetghebeur, M., Schellenberg, R. (2012). Economic benefit of subcutaneous rapid push versus intravenous infusion therapy in adult patients with primary immune deficiency. Allergy, Asthma and Clinical Immunology, 8(suppl. 1) A20.

Misbah, S., Sturzenegger, M.H., Borte, M., Shapiro, R.S., Wasserman, R.L., Berger, M., & Ochs, H.D. (2009). Subcutaneous immunoglobulin: Opportunities and outlook. Clinical and Experimental Immunology, 158(Suppl. 1), 51–59.

Morra, E, Nosari, A., & Montillo, M. (1999). Infectious complications in chronic lymphocytic leukemia. Hematology and Cell Therapy. 41, 145–151.

Morrison, V. (2010). Infectious complications of chronic lymphocytic leukemia: Pathogenesis, spectrum of infection, preventive approaches. Best Practice and Research Clinical Hematology, 23(1), 145–153.

Navarro, R.P. (2012). Considerations for the Optimal Use of Immunoglobulins. American Journal of Managed Care, 18, 4s.

Nicolay, U., Kiessling, P., Berger, M., Gupta, S., Yel, L., Roifman, C., et al. (2006). Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency disease receiving subcutaneous IgG self-infusion at home. Journal of Clinical Immunology, 26(1), 65–72.

Orange, J.S., Belohradsky, B.H., Berger, M., Borte, M., Hagan, J., Jolles, S., et al., (2012). Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clinical and Experimental Immunology, 169, 172–181.

Oscier, D., Dearden, C., Eren, E., Erem, E., Fegan, C., Follows, G., et al., (2012). Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukemia. British Journal of Hematology, 159, 541–564.

Parikh, S.A., Leis, J.F., Chaffee, K.G., Call, TG, Hanson, C.A., Ding, W., et al. (2015). Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates and outcomes. Cancer, 121(17), 2883–2891.

Shelton, B., Griffin, J.M., & Goldman, F.D. (2006). Immune globulin IV therapy: optimizing care of patients in the oncology setting. Oncology Nursing Forum, 33(5), 911–921.

Skoda-Smith, S., Torgerson, T.R., & Ochs, H.D. (2010). Subcutaneous immunoglobulin replacement in the treatment of patients with primary immunodeficiency. Journal of Therapeutics and Clinical Risk Management, 2(6), 1–10.


Refbacks

  • There are currently no refbacks.


Bookmark and Share